Elicio Therapeutics, Inc. - Common Stock

ELTX39

$5.07arrow_drop_down1.36%-$0.07

ELTX39

$5.07

arrow_drop_down1.36%-$0.07

Performance History

Key Stats
Open	$5.01
Prev. Close	$5.14
EPS	0.92
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$54.84M

	LOW	HIGH
Day Range	5.00	5.08
52 Week Range	2.96	11.45

Ratios

Revenue	-



EBITDA Margin %	-

EPS	0.92

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Elicio Therapeutics, Inc. - Common Stock (ELTX)

Elicio Therapeutics, Inc. (ELTX) is a biotechnology company focused on developing highly targeted immunotherapies for the treatment of cancer and other diseases. The company's innovative approach is based on its proprietary Amphiphile technology, which enables the delivery of immunotherapies directly to the lymph nodes, where immune responses are initiated. By targeting the lymphatic system, Elicio's therapies have the potential to generate robust and durable immune responses against tumor cells.

ELTX is committed to revolutionizing cancer treatment by harnessing the power of the immune system. The company's lead product candidate, ELTX-101, is a personalized cancer immunotherapy that combines the patient's own tumor antigens with Elicio's Amphiphile platform. By delivering tumor antigens directly to the lymph nodes, ELTX-101 aims to stimulate a targeted immune response against the patient's specific cancer cells. Preliminary results from a Phase 1/2 clinical trial have shown promising safety and efficacy data, with several patients experiencing tumor shrinkage or stabilization.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Robert T. Connelly
Headquarters: Boston
Employees: 23
Exchange: NASDAQ

add Elicio Therapeutics, Inc. - Common Stock to watchlist

Keep an eye on Elicio Therapeutics, Inc. - Common Stock

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Elicio Therapeutics, Inc. - Common Stock's (ELTX) price per share?

The current price per share for Elicio Therapeutics, Inc. - Common Stock (ELTX) is $5.07. The stock has seen a price change of -$0.07 recently, indicating a -1.36% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Elicio Therapeutics, Inc. - Common Stock (ELTX)?

For Elicio Therapeutics, Inc. - Common Stock (ELTX), the 52-week high is $11.45, which is 125.84% from the current price. The 52-week low is $2.96, the current price is 71.28% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Elicio Therapeutics, Inc. - Common Stock (ELTX) a growth stock?

Elicio Therapeutics, Inc. - Common Stock (ELTX) has shown an average price growth of 0.41% over the past three years. It has received a score of 14 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Elicio Therapeutics, Inc. - Common Stock as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Elicio Therapeutics, Inc. - Common Stock (ELTX) stock price performance year to date (YTD)?

As of the latest data, Elicio Therapeutics, Inc. - Common Stock (ELTX) has a year-to-date price change of -14.5%. Over the past month, the stock has experienced a price change of 12.17%. Over the last three months, the change has been -23.41%. Over the past six months, the figure is -23.18%.

help

Is Elicio Therapeutics, Inc. - Common Stock (ELTX) a profitable company?

Elicio Therapeutics, Inc. - Common Stock (ELTX) has a net income of -$35.2M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$35.74M. Furthermore, the EBITDA is -$41M.

help

What is the market capitalization of Elicio Therapeutics, Inc. - Common Stock (ELTX)?

Elicio Therapeutics, Inc. - Common Stock (ELTX) has a market capitalization of $54.84M. The average daily trading volume is 17.74K, indicating the stock's liquidity and investor engagement.

News

Elicio Therapeutics Announces Proposed Public Offering

MANAGEMENT STATEMENTS

6/27/2024

Elicio Therapeutics Announces Proposed Public Offering

Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P

HEALTH

PRODUCT / SERVICES ANNOUNCEMENT

CLINICAL STUDY

6/27/2024

Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P

Elicio Therapeutics Reports Inducement Grants

CHANGES IN COMPANY'S OWN SHARES

6/18/2024

Elicio Therapeutics Reports Inducement Grants

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

CALENDAR OF EVENTS

HEALTH

PRODUCT / SERVICES ANNOUNCEMENT

CLINICAL STUDY

5/23/2024

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates

EARNINGS RELEASES AND OPERATING RESULTS

5/15/2024

Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

CALENDAR OF EVENTS

CLINICAL STUDY

4/5/2024

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

Performance History

Score Breakdown

Welcome to Stocklytics

Analyst Forecast

Analyst Ratings

About Elicio Therapeutics, Inc. - Common Stock (ELTX)

Keep an eye on Elicio Therapeutics, Inc. - Common Stock

Frequently Asked Questions

What is Elicio Therapeutics, Inc. - Common Stock's (ELTX) price per share?

What is the 52-week high and low for Elicio Therapeutics, Inc. - Common Stock (ELTX)?

Is Elicio Therapeutics, Inc. - Common Stock (ELTX) a growth stock?

What is Elicio Therapeutics, Inc. - Common Stock (ELTX) stock price performance year to date (YTD)?

Is Elicio Therapeutics, Inc. - Common Stock (ELTX) a profitable company?

What is the market capitalization of Elicio Therapeutics, Inc. - Common Stock (ELTX)?

News

Sign up for our newsletter

Take Your Investments to a Whole New Level